Adagrasib is an oral Kirsten Rat Sarcoma Virus (KRAS) inhibitor designed to potently and selectively target the KRAS G12C mutation. It received accelerated approval from the US FDA in 2022 for the treatment of NSCLC and has demonstrated durable clinical benefits, including improved progression-free survival . Notably, in 2024, the US FDA also granted accelerated approval for adagrasib in combination with immunotherapy for adults with KRAS G12C-mutated colorectal cancer, further reinforcing its potential across multiple tumour types. Adagrasib primary patents have been filed in many LMICs and are expected to expire in 2038.

Acronyms & abbreviations list